Elicio Therapeutics, Inc. (NASDAQ:ELTX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Posted by George Bondi on Jun 10th, 2026

Shares of Elicio Therapeutics, Inc. (NASDAQ:ELTX – Get Free Report) have earned a consensus rating of “Moderate Buy” from the five ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $20.25.

ELTX has been the subject of several analyst reports. Rodman & Renshaw raised shares of Elicio Therapeutics to a “strong-buy” rating in a report on Tuesday, March 10th. HC Wainwright reiterated a “buy” rating and issued a $17.00 target price on shares of Elicio Therapeutics in a research note on Thursday, May 28th. B. Riley Financial assumed coverage on Elicio Therapeutics in a report on Wednesday. They issued a “buy” rating and a $27.00 price objective on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Elicio Therapeutics in a research report on Friday, April 24th. Finally, LADENBURG THALM/SH SH began coverage on Elicio Therapeutics in a research note on Wednesday, April 15th. They set a “buy” rating and a $20.00 price objective on the stock.

Check Out Our Latest Analysis on ELTX

Elicio Therapeutics Price Performance

Shares of ELTX traded up $1.08 during midday trading on Wednesday, hitting $15.28. The company’s stock had a trading volume of 43,342 shares, compared to its average volume of 131,782. The stock has a market capitalization of $291.70 million, a price-to-earnings ratio of -6.37 and a beta of 1.13. The company’s fifty day simple moving average is $11.13 and its two-hundred day simple moving average is $9.83. The company has a quick ratio of 2.24, a current ratio of 2.24 and a debt-to-equity ratio of 5.75. Elicio Therapeutics has a one year low of $7.37 and a one year high of $16.00.

Elicio Therapeutics (NASDAQ:ELTX – Get Free Report) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.16). As a group, equities analysts expect that Elicio Therapeutics will post -1.87 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in shares of Elicio Therapeutics by 4.2% during the third quarter. Vanguard Group Inc. now owns 473,859 shares of the company’s stock worth $5,184,000 after acquiring an additional 19,240 shares during the period. Geode Capital Management LLC grew its position in shares of Elicio Therapeutics by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 132,518 shares of the company’s stock worth $1,055,000 after buying an additional 2,832 shares during the period. Renaissance Technologies LLC increased its holdings in Elicio Therapeutics by 332.7% during the 1st quarter. Renaissance Technologies LLC now owns 121,631 shares of the company’s stock worth $1,300,000 after purchasing an additional 93,520 shares in the last quarter. Susquehanna International Group LLP increased its holdings in Elicio Therapeutics by 606.1% during the third quarter. Susquehanna International Group LLP now owns 120,207 shares of the company’s stock worth $1,315,000 after buying an additional 103,184 shares during the last quarter. Finally, Marshall Wace LLP lifted its holdings in Elicio Therapeutics by 35.4% during the 4th quarter. Marshall Wace LLP now owns 117,200 shares of the company’s stock worth $933,000 after purchasing an additional 30,667 shares in the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Elicio Therapeutics

(Get Free Report)

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.